Bacterial compositions for prophylaxis and treatment of degenerative disease

A composition and bacterial technology, applied in the direction of bacteria, metabolic diseases, blood diseases, etc., can solve problems such as side effects, physical discomfort, and flushing of the whole body

Inactive Publication Date: 2012-05-30
MICROPHARMA
View PDF2 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Unfortunately, taking these drugs on a regular basis can be associated with discomfort and serious side effects, including flushing of the face and body

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bacterial compositions for prophylaxis and treatment of degenerative disease
  • Bacterial compositions for prophylaxis and treatment of degenerative disease
  • Bacterial compositions for prophylaxis and treatment of degenerative disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2-

[0192] Example 2 - High BSH Activity

[0193] General Materials and Methods

[0194] Bacterial inoculation and growth: Glycerol-frozen bacterial stocks were picked with sterile wooden sticks on MRS agar plates. Incubate overnight under anaerobic conditions at 37°C. Under aseptic conditions, pick up the L. reuteri NCIMB 701359 monoclonal colony with a metal ring and transfer it to a tube containing 10 mL of MRS. Incubation overnight at 37°C is convenient for experiments.

[0195] Microcapsule encapsulation of L. reuteri NCIMB 701359: Microcapsules were prepared with 200 μm orifice, 8% cells and 1.75% concentration of sodium alginate. The embedding process is as follows: First, the CaCl 2Discharge the sodium alginate microspheres; second, wash the sodium alginate microspheres with 0.85% (w / v) NaCl for 10 min; third, embed the sodium alginate microspheres with 0.1% (w / v) ε-PLL for 20 min; Fourth, wash sodium alginate-PLL microcapsules with 0.85% (w / v) NaCl for 10 min; fif...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The disclosure provides an oral composition for reducing serum cholesterol, serum lipids, body fat, or atherogenic index or for prophylaxis or treatment of atherosclerosis, cardiovascular or cerebrovascular diseases, comprising a highly bsh active bacteria, isolate or supernatant thereof; wherein the highly bsh active bacteria degrades >50[mu]mol glycodeoxycholic acid (GDCA) / gram / hour and >2[mu]mol taurodeoxycholic acid (TDCA) / gram / hour when measured over 1 hour and 5 hours, respectively, or degrades >65 [mu]mol GDCA / g / hr and >7 [mu]mol TDCA / g / hr when measured over 30 minutes.

Description

[0001] Related Patent Applications [0002] This application claims the benefit of and priority to co-pending US Provisional Patent Application No. 61 / 174,740, filed May 1, 2009, the entire disclosure of which is incorporated herein by reference in its entirety. technical field [0003] The present disclosure relates to an improved oral composition of bacteria with high bsh activity, its isolate or supernatant, and the process for preparing the improved composition. The present disclosure also relates to methods and uses of the improved oral composition, including reducing serum cholesterol, blood lipid, body fat or atherosclerosis index, and preventing and treating atherosclerosis, cardiovascular or cerebrovascular diseases. technical background [0004] Hypercholesterolemia and Coronary Artery Disease [0005] Coronary artery disease (CAD) is the leading cause of death in Western countries, the most common heart disease and the most common cause of sudden death. Clinical...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/74A61K9/50A61K9/51A61P1/16A61P3/04A61P3/06A61P9/10C12N1/04C12N1/20C12N9/78C12N11/02C12N11/04A61K35/744A61K35/747
CPCA23Y2220/71A61K9/1652A61K35/747A23C9/1234A61K35/744A23L1/3014A61K9/5031A23V2002/00C12R1/225C12N1/20A61K9/1664C12N11/10A23C2220/204A61K9/5036A23L33/135A61P1/16A61P13/12A61P25/00A61P3/00A61P3/04A61P31/22A61P35/00A61P3/06A61P37/06A61P43/00A61P5/50A61P7/02A61P9/00A61P9/08A61P9/10A61P9/14A61P3/10Y02A90/10C12R2001/225C12N1/205A23V2400/173A23V2200/224A23V2200/3204A23V2200/3262A61K9/0053A61K9/51A61K31/575
Inventor S·普拉卡什M·L·琼斯C·马尔托尼
Owner MICROPHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products